. .

 
Zuruecksetzen

Suchergebnis - Johnson & Johnson

Zeit Titel
13.06 17:02dpa-AFX: *JOHNSON & JOHNSON REPORTS INITIAL PHASE 1B DATA FOR DUAL-TARGETING CAR-T THERAPY JNJ-4496 IN R/R LARGE B-CELL LYMPHOMA
12.06 17:02dpa-AFX: *J&J REPORTS PROMISING EARLY TRIAL RESULTS FOR LEUKEMIA DRUG COMBO TARGETING AML WITH GENE MUTATIONS
11.06 14:31dpa-AFX: Johnson & Johnson: TREMFYA Significantly Reduces Symptoms Of PsA In APEX Study
11.06 14:07dpa-AFX: *JOHNSON & JOHNSON'S TREMFYA SHOWS SIGNIFICANT IMPROVEMENT IN PSORIATIC ARTHRITIS IN PHASE 3B APEX STUDY
03.06 19:27dpa-AFX: Johnson & Johnson's DARZALEX FASPRO Improves Myeloma Survival And MRD Response Rates
03.06 18:53dpa-AFX: Johnson & Johnson Says Carvykti Achieved Treatment-free Remissions For 5 Years In Myeloma Patients
03.06 17:06dpa-AFX: Johnson & Johnson's Trispecific Antibody Show Promising Response In Myeloma Patients
03.06 16:59dpa-AFX: *JOHNSON & JOHNSON'S DARZALEX FASPRO QUADRUPLET ACHIEVES DEEP MRD RESPONSE, ENHANCES PFS IN NDMM
03.06 16:57dpa-AFX: *J&J : CARVYKTI SINGLE INFUSION DELIVERS 5-YEAR TREATMENT-FREE REMISSIONS IN R/R MULTIPLE MYELOMA
03.06 16:56dpa-AFX: *J&J'S TRISPECIFIC ANTIBODY SHOWS PROMISING EARLY RESPONSE IN HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS
03.06 14:52dpa-AFX: Johnson & Johnson Reports Positive Results From Phase 3 AMPLITUDE Study In Prostate Cancer
03.06 14:05dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PROMISING PHASE 3 RESULTS FOR NIRAPARIB COMBO IN METASTATIC PROSTATE CANCER
28.05 14:04dpa-AFX: Johnson & Johnson To Present At Bernstein's Strategic Decisions Conference; Webcast At 9:00 AM ET
23.05 15:13dpa-AFX: Medical Experts Urge FDA To Adopt New Policies To Prohibit Talc Use In Consumer Products
23.05 14:04dpa-AFX: *FDA EXPERTS URGE BAN ON TALC IN CONSUMER PRODUCTS, CITING HEALTH CONCERNS
21.05 04:03dpa-AFX: FDA Panel Votes In Favor Of J&J' DARZALEX FASPRO For High-Risk Smoldering Multiple Myeloma Treatment
09.05 17:20dpa-AFX: JNJ's Icotrokinra Shows Positive Phase 3 Results In Scalp, Genital Psoriasis
09.05 14:08dpa-AFX: *JOHNSON & JOHNSON'S ICOTROKINRA SHOWS SIGNIFICANT SKIN CLEARANCE IN PHASE 3 PSORIASIS STUDY
05.05 15:33dpa-AFX: Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis
05.05 14:50dpa-AFX: J&J Reports Positive Data From Long-term Extension Study Of TREMFYA In Ulcerative Colitis

© 2000-2025 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2025 Infront Financial Technology GmbH